2015 | TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC | Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony | J. Thorac. Oncol. | | | |
2023 | TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC | Levy, Benjamin P; Felip, Enriqueta; Reck, Martin; CHIH-HSIN YANG ; Cappuzzo, Federico; Yoneshima, Yasuto; Zhou, Caicun; Rawat, Siddhartha; Xie, Jingdong; Basak, Priyanka; Xu, Lu; Sands, Jacob | Future oncology (London, England) | 2 | 1 | |